• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Veev Bolsters C-Suite, Appoints Gordon Heneweer as CFO

    4/4/22 9:00:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email

    SAN MATEO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Today Veev, the technology-enabled homebuilding company, announced the latest addition to its leadership team, naming Gordon Heneweer as Chief Financial Officer. Heneweer will oversee all finance and accounting functions including the Corporate Controllership, FP&A, project finance, Treasury, Tax and business operations, as well as corporate strategy.

    Veev has achieved a novel approach to homebuilding that views the home as the ultimate consumer product––a highly personal space that should enhance and reflect the lives of the people who live there. Grounded in this consumer-first focus, Veev has pioneered a breakthrough technological approach to building turnkey, high-quality homes faster and at a lower cost than traditional construction.

    "Gordon's business acumen and strategic leadership experience align seamlessly with Veev's expansion efforts and will be a major asset for our company," said Amit Haller, Veev CEO and co-founder. "His career is noteworthy, not only for his success in driving strong financial performance, but also for his track record of leading diverse, capable, and innovative teams. At Veev, we're tackling one of the most challenging issues facing the world today, and bringing aboard leaders like Gordon advances our mission to bring exceptional living to all."

    Heneweer joins Veev at a time of rapid growth for the company, having recently achieved unicorn status, raised $400 million in Series D financing, and announced a major partnership with Lennar. Now, the company remains focused on scaling operations by replicating its successful wheel-and-spoke model, or "Fab-in-a-Box," to new markets. The strategy, which capitalizes on building Digital Fab facilities near demand, allows the company to streamline manufacturing, transportation, and assembly––building up to 4x the speed and at a fraction of the cost of traditional means.

    "Veev has created a revolutionary approach to solving the housing crisis, leveraging cutting-edge technology and developing a unique vision for what the home should be," said Gordon Heneweer. "I'm eager to get to work alongside this brilliant team, and I look forward to advancing Veev's bold vision for the future of homebuilding and how we experience the home."

    Prior to Veev, Heneweer served as CFO for the past 10 years at CooperVision (NYSE:COO), a $2B+ revenue medical device manufacturer and distributor. He was a key member of CooperVision's executive leadership team, leading and directing all aspects of the organizations' financial strategy and operations, including oversight of the global IT function. Gordon's esteemed career also includes senior financial leadership positions of increasing responsibility at Electronics for Imaging, Inc., Applied Materials, Inc., and New United Motor Manufacturing, Inc. (NUMMI).

    To learn more about Veev, visit https://veev.com/.

    About Veev

    Veev is a building technology company founded on the belief that homes are the ultimate consumer product, and they need to be built better, and faster. Working across design, development, engineering, manufacturing, and construction, Veev has developed a vertically integrated approach to productize the home and improve on cost and quality, up to 4x the speed of traditional construction. Veev is focused on building multi-family homes and single-family homes at scale, helping develop and support communities, and improving our quality of living.

    Contact

    LaunchSquad for Veev

    [email protected]

     



    Primary Logo

    Get the next $COO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    5/30/2025$76.00Overweight → Neutral
    Analyst
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    3/13/2024$100.00 → $120.00Neutral → Overweight
    JP Morgan
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    10/30/2023$380.00Buy
    BofA Securities
    10/5/2023$390.00 → $343.00Overweight → Neutral
    Redburn Atlantic
    More analyst ratings

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/16/24 4:57:01 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G filed by The Cooper Companies Inc.

      SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/14/24 10:04:33 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/13/24 5:02:29 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Financials

    Live finance-specific insights

    See more
    • CooperCompanies Announces Second Quarter 2025 Results

      SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

      5/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for Second Quarter 2025

       SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

      4/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces First Quarter 2025 Results

      SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "We started the y

      3/6/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cooper downgraded by Analyst with a new price target

      Analyst downgraded Cooper from Overweight to Neutral and set a new price target of $76.00

      5/30/25 8:39:00 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Piper Sandler reiterated coverage on Cooper with a new price target

      Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously

      8/29/24 8:24:13 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper upgraded by Jefferies with a new price target

      Jefferies upgraded Cooper from Hold to Buy and set a new price target of $115.00 from $107.00 previously

      7/16/24 7:26:08 AM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Carbone Barbara

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:16:23 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 3 filed by new insider Carbone Barbara

      3 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:14:05 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Kozy William A converted options into 2,857 shares, increasing direct ownership by 10% to 31,149 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:09:38 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    SEC Filings

    See more
    • SEC Form SD filed by The Cooper Companies Inc.

      SD - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/30/25 4:20:18 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by The Cooper Companies Inc.

      10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/30/25 4:19:23 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 8-K filed by The Cooper Companies Inc.

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/29/25 4:31:50 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CooperCompanies Announces Second Quarter 2025 Results

      SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

      5/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies' 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet

      SAN RAMON, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CooperCompanies ("Cooper") (NASDAQ:COO), a leading medical device company, published its 2024 Sustainability Report. The report showcases the company's initiatives to foster positive change for both people and the planet and provides expanded and updated sustainability performance data. In 2024, CooperCompanies maintained strong partnerships to reduce its plastic footprint, earned a number of sustainability certifications, and supported employee growth with significant investments in learning and development programs for employees. "Our 2024 Sustainability Report reflects Cooper's commitment to help people experience life's beautiful m

      5/20/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies to Participate in the William Blair Growth Stock Conference

      SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled at 11:20 AM CT. The webcast will be available to investors and other interested parties by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two bu

      5/8/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    See more
    • CooperCompanies Appoints Barbara Carbone to Board of Directors

      SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

      4/30/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

      SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo

      11/30/23 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care